Dr Aris Angelis


Assistant Professor

15-17 Tavistock Place
United Kingdom

Dr Aris Angelis is an Assistant Professor in Health Economics with the Department of Health Services Research and Policy at the London School of Hygiene and Tropical Medicine (LSHTM). Before joining LSHTM, Aris was at the London School of Economics and Political Science (LSE), working as a Research Fellow at LSE Health and a Guest Teacher at the Department of Health Policy, where he is now a Visiting Fellow.

Aris received his Doctor of Philosophy (PhD) in Pharmaceutical Policy and Economics from the Department of Social Policy at LSE. His PhD investigated the development and application of a methodological framework based on Multiple Criteria Decision Analysis (MCDA) for assessing the value of new medical technologies in the context of HTA, to inform resource allocation decisions and incentivise socially desirable R&D investments. He also holds an MSc in International Health Policy from the LSE, an MSc in Biopharmacy from King’s College London and a BSc in Biochemistry from Imperial College London.


Department of Health Services Research and Policy
Faculty of Public Health and Policy


Aris’ main interests are in Health Technology Assessment (HTA) with a focus on multi-disciplinary methodological and applied health services research for health care evaluation using health economics and decision analysis. He will be leading the development of a research programme for assessing the value of new oncology products at an early stage using decision analytic modeling techniques and will be collaborating with the Center for Health Policy & Outcomes at the Memorial Sloan Kettering Cancer Center. At LSE, most recently Aris has been involved with the EU funded project Impact-HTA, co-leading the research activities of a work package on multi-criteria value methods and working towards a new value framework for medicines in collaboration with different HTA bodies. He is also involved in a project initiative with the European Society for Medical Oncology (ESMO), co-leading research activities towards the development of an ESMO value framework for cancer medicines. In the past, Aris has undertaken contracted research, training and advisory work for the European Commission, the World Health Organization, national health ministries and various biopharmaceutical organisations.

Google Scholar page:

Research Area
Decision analysis
Health policy
Health services research
Health technology assessment
Health economics
European Union
North America

Selected Publications

Evidence generation and reproducibility in cell and gene therapy research: A call to action.
Abou-El-Enein M; Angelis A; Appelbaum FR; Andrews NC; Bates SE; Bierman AS; Brenner MK; Cavazzana M; Caligiuri MA; Clevers H
Molecular therapy. Methods & clinical development
The Need for Novel Approaches in Assessing the Value of COVID-19 Vaccines
Angelis A; Baltussen R; Tervonen T
American Journal of Public Health
Results of the Web-Delphi process to INAMI stakeholders (three rounds)
Oliveira MD; Dimitrovová K; Angelis A; Kanavos P; Bana e Costa C
Results of the Web-Delphi process to YLV stakeholders (three rounds)
Oliveira MD; Dimitrovová K; Angelis A; Kanavos P; Bana e Costa C
ICER Value Framework 2020 Update: Recommendations on the Aggregation of Benefits and Contextual Considerations.
Angelis A; Kanavos P; Phillips LD
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis.
Angelis A; Thursz M; Ratziu V; O'Brien A; Serfaty L; Canbay A; Schiefke I; Costa JBE; Lecomte P; Kanavos P
See more Publications